SAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth
Launched by JENNIFER HUGHES · Jun 11, 2024
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This research project has iterative aims focused on the development and pilot testing of the SAFETY-P asynchronous parent intervention module. Phase 1 will focus on finalizing SAFETY-P content for the online learning module. Phase 2 will be a small open case series integrating additional key stakeholder feedback via formative usability testing. Phase 3 will test the revised module in a pilot RCT, to establish methods and protocols for a future large-scale clinical trial.
Phase 1/Aim 1 (Intervention Adaptation for Online Delivery): Phase 1 will include 4 separate stakeholder focus groups (a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For Phase 1 interviews and focus groups:
- • 1. Youth or young adults (\<25 years) with prior suicidal ideation or suicide attempts; parents whose child had a history of suicidal ideation and/or suicide attempt before age 18; medical or behavioral health provider of suicidal youth; and parents whose child died from suicide before age 18
- For Phase 2 and the Phase 3:
- • 1. Youth is currently in treatment with the Critical Assessment and Treatment Clinic (CATC) at NCH for suicidal thoughts or behaviors
- • 2. Youth is between the ages of 10-18 (18-year-old youth must still be in high school and living at home with parents for duration of the study)
- • 3. At least one parent is able to participate
- • 4. Youth and parent are fluent in English
- Exclusion Criteria:
- For all four Phase 1 groups:
- • 1. Cannot read or speak English (given focus group to be conducted in English
- For Phase 2 and Phase 3 participants:
- • 1. The youth or parent has an acute psychiatric or medical condition that would interfere with their ability to participate in study procedures
- • 2. Lack of access to a digital device (smartphone, iPad, tablet computer, desktop, laptop PC)
About Jennifer Hughes
Jennifer Hughes is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical pharmacology and extensive experience in trial design and management, she leads initiatives that focus on innovative therapies and evidence-based practices. Her collaborative approach fosters partnerships with research institutions and healthcare professionals, ensuring that trials are conducted with the highest standards of ethics and scientific rigor. Through her leadership, Jennifer aims to contribute to the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Jennifer L Hughes, PhD, MPH
Principal Investigator
Nationwide Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported